PIII vs. KOD, TELO, VCXB, CLPT, SMLR, IXHL, CLLS, ADVM, MDWD, and ACHV
Should you be buying P3 Health Partners stock or one of its competitors? The main competitors of P3 Health Partners include Kodiak Sciences (KOD), Telomir Pharmaceuticals (TELO), 10X Capital Venture Acquisition Corp. III (VCXB), ClearPoint Neuro (CLPT), Semler Scientific (SMLR), Incannex Healthcare (IXHL), Cellectis (CLLS), Adverum Biotechnologies (ADVM), MediWound (MDWD), and Achieve Life Sciences (ACHV). These companies are all part of the "medical" sector.
Kodiak Sciences (NASDAQ:KOD) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.
89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 45.3% of Kodiak Sciences shares are owned by insiders. Comparatively, 17.9% of P3 Health Partners shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Kodiak Sciences currently has a consensus price target of $5.50, suggesting a potential upside of 80.33%. P3 Health Partners has a consensus price target of $4.75, suggesting a potential upside of 748.21%. Given Kodiak Sciences' stronger consensus rating and higher possible upside, analysts clearly believe P3 Health Partners is more favorable than Kodiak Sciences.
Kodiak Sciences received 14 more outperform votes than P3 Health Partners when rated by MarketBeat users. However, 28.57% of users gave P3 Health Partners an outperform vote while only 28.13% of users gave Kodiak Sciences an outperform vote.
Kodiak Sciences has a beta of 2.25, meaning that its stock price is 125% more volatile than the S&P 500. Comparatively, P3 Health Partners has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
Kodiak Sciences has a net margin of 0.00% compared to Kodiak Sciences' net margin of -4.97%. Kodiak Sciences' return on equity of -79.03% beat P3 Health Partners' return on equity.
In the previous week, P3 Health Partners had 2 more articles in the media than Kodiak Sciences. MarketBeat recorded 4 mentions for P3 Health Partners and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.25 beat P3 Health Partners' score of 1.20 indicating that P3 Health Partners is being referred to more favorably in the news media.
P3 Health Partners has higher revenue and earnings than Kodiak Sciences. P3 Health Partners is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
P3 Health Partners beats Kodiak Sciences on 11 of the 17 factors compared between the two stocks.
Get P3 Health Partners News Delivered to You Automatically
Sign up to receive the latest news and ratings for PIII and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PIII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
P3 Health Partners Competitors List
Related Companies and Tools
